ClinicalTrials.gg
TerminatedNCT05259631Updated Nov 10, 2026

Inhalational (Sevoflurane) Versus Intravenous (Propofol) Sedation in Adults With a Moderate Form of ARDS

A Phase 3 interventional study of Sevoflurane and Propofol in Acute Respiratory Distress Syndrome, sponsored by Negovsky Reanimatology Research Institute. Terminated at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Negovsky Reanimatology Research Institute · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Financial problems
Updated Nov 10, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The American European Consensus Conference (AECC) 1994 defined acute respiratory distress syndrome (ARDS) as an acute inflammatory syndrome manifesting as diffuse pulmonary edema and respiratory failure that cannot be explained by, but may co-exist with, left-sided heart failure. During the sequel Conference of the European Society of Intensive Care Medicine, in 2012 minor changes were made, and since that so-called Berlin definition of ARDS is used worldwide for the description of this severe disease. Three grades of severity were proposed to distinguish ARDS according to the level of hypoxemia with a mortality of 24% in patients with mild ARDS, rising to 48% in those with severe ones.

Systemic inflammation is considered to be the main reason of ARDS. Activated neutrophils interact with the alveolar-capillary membrane causing the increasing permeability with the sequence lung edema's development. Inflammatory exudate inactivates surfactant leading to collapse and consolidation of distal airspaces with progressive loss of the lung's gas exchange surface area. Unfortunately, systemic inflammatory response syndrome (SIRS) simultaneously inhibits the mechanism of active pulmonary vasoconstriction and allows deoxygenated blood to pass through unventilated areas of the lung boosting the right-to-left shunt. Both mechanisms lead to hypoxemia, which is the main and obligatory feature of ARDS.

Actually, endothelial dysfunction and transcapillary leakage seem to be one of the main steps in the development of respiratory failure during ARDS. Last decades it was found out that glycocalyx is also participating in this process too.

Thus, it became clear that substances preserving endothelium and glycocalyx from SIRS-causing damage may have a beneficial effect in ARDS treatment. It seems to be crucially important so as the majority of drugs failed to demonstrate any positive effects in terms of ARDS treatment.

To the moment we have some evidence, which came from experimental studies, that halogenated anesthetics can preserve glycocalyx against ischemia-reperfusion injury.

The primary objective for the multicentral INVERSE Trial will be to determine the effects of inhalational (sevoflurane) versus intravenous (propofol) sedation on P/F ratio on the second day, hospital mortality and ICU (intensive care unit), and in-hospital length of stay in adults with a moderate form of ARDS.

02

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • Acute Respiratory Distress Syndrome
  • Sedation
  • Sevoflurane
  • Propofol
  • Volatile anesthetics
  • Intravenous anesthetics
  • Inhalational anesthetics
  • Intensive care unit
03

In context

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

This study's enrollment of 2 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18
  • Endotracheal intubation or tracheostomy
  • Timing: Acute onset of new or worsening of chronic respiratory symptoms within 72 hours before the randomization
  • Chest imaging: Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules
  • Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload
  • Oxygenation: 100 mm Hg \< PaO2/FiO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O

Exclusion criteria

Exclusion Criteria:

  • History or family history of malignant hyperthermia
  • History of propofol infusion syndrome
  • Documented or suspected increased intracranial pressure
  • Chronic restrictive pulmonary disease
  • Neuromuscular disease
  • Chest wall disorder
  • Pulmonary vascular disease
  • class ≥ 3
  • Severe pulmonary hypertension (mean pulmonary artery pressure > 40 mmHg)
  • Documented ongoing COVID-19 infection
  • Ongoing therapy
  • Previous randomization in this trial
  • Post randomization exclusion criterion: Documented ongoing COVID-19 infection during the first 48 hours after the randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Inhalational sedation

    Drug: Sevoflurane

  • Active comparator
    Intravenous sedation

    Drug: Propofol

Interventions

  • Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation

  • Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation

06

What researchers measure

Primary outcomes

  1. P/F ratio

    PaO2 divided on FiO2

    Time frame: day 2 after the randomization

Secondary outcomes

  1. 28-days mortality

    number of deaths

    Time frame: 28 day

  2. 6-months mortality

    number of deaths

    Time frame: 6 months

  3. 1-year mortality

    number of death

    Time frame: 1 year

  4. Length of stay in the intensive care unit

    number of days in the intensive care unit

    Time frame: 1 year

  5. Length of hospitalization

    number of days in hospital

    Time frame: 1 year

  6. Ventilator free days in ICU

    number of days in ICU - number of days on mechanical ventilation

    Time frame: 1 year

  7. Ventilator free days during hospitalization

    Length of hospitalization - number of days on mechanical ventilation

    Time frame: 1 year

07

Study locations

1 site
  • Demikhov Municipal Clinical Hospital 68
    Moscow, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2022 to primary completion in Jan 2023, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Feb 2025 → Jan 2023 and completion Feb 2026 → Jan 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Feb 28, 2022
StartActual
Mar 14, 2022
Primary completionActual
Jan 20, 2023was Feb 2025
CompletionActual
Jan 20, 2023was Feb 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated
changed Nov 10, 2026
Primary completion
Feb 25, 2025→Jan 20, 2023 (actual)
Nov 10, 2026
Study completion
Feb 25, 2026→Jan 20, 2023 (actual)
Nov 10, 2026
Enrollment
310 (estimated)→2 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Suspended→Terminated
    Primary completion Feb 25, 2025→Jan 20, 2023 (now actual)
    Study completion Feb 25, 2026→Jan 20, 2023 (now actual)
    Enrollment 310 (estimated)→2 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05259631
Lead sponsor
Negovsky Reanimatology Research Institute
Responsible party
Valery Likhvantsev, MD (Head of the Research V. Negovsky Reanimatology Research Institute, Negovsky Reanimatology Research Institute) — Principal investigator
First posted
Feb 28, 2022
Start date
Mar 14, 2022
Primary completion
Jan 20, 2023
Completion
Jan 20, 2023
Last update
Nov 10, 2026

Study contacts

Valery Likhvantsev
principal investigator · Negovsky Reanimatology Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevoflurane

Start the discussion